Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, et al. Expert Opinion on Drug Safety. 2022:1-8
Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, et al. A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home. Expert Opinion on Drug Safety. 2022:1-8.